0NLV Stock Overview
VITA 34 AG engages in the collection, processing, and cryopreservation of stem cells from umbilical cord blood and tissue in Germany, Poland, Portugal, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
VITA 34 AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.40 |
| 52 Week High | €6.44 |
| 52 Week Low | €3.92 |
| Beta | 0.62 |
| 1 Month Change | 0% |
| 3 Month Change | 12.24% |
| 1 Year Change | n/a |
| 3 Year Change | -66.02% |
| 5 Year Change | -67.59% |
| Change since IPO | -63.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0NLV | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | -1.3% |
| 1Y | n/a | -28.6% | -1.8% |
Return vs Industry: Insufficient data to determine how 0NLV performed against the UK Healthcare industry.
Return vs Market: Insufficient data to determine how 0NLV performed against the UK Market.
Price Volatility
| 0NLV volatility | |
|---|---|
| 0NLV Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0NLV has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0NLV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 815 | Jakub Baran | www.vita34.de |
VITA 34 AG engages in the collection, processing, and cryopreservation of stem cells from umbilical cord blood and tissue in Germany, Poland, Portugal, and internationally. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces viral vectors and CAR-T cells. The company manufactures advanced therapy medicinal products for third parties.
VITA 34 AG Fundamentals Summary
| 0NLV fundamental statistics | |
|---|---|
| Market cap | €83.32m |
| Earnings (TTM) | -€24.83m |
| Revenue (TTM) | €74.86m |
1.1x
P/S Ratio-3.4x
P/E RatioIs 0NLV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0NLV income statement (TTM) | |
|---|---|
| Revenue | €74.86m |
| Cost of Revenue | €49.00m |
| Gross Profit | €25.86m |
| Other Expenses | €50.69m |
| Earnings | -€24.83m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.42 |
| Gross Margin | 34.54% |
| Net Profit Margin | -33.18% |
| Debt/Equity Ratio | 105.1% |
How did 0NLV perform over the long term?
See historical performance and comparison